192 related articles for article (PubMed ID: 29945143)
1. Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study.
Sharma S; Khan MA; Chaturvedi A;
Ophthalmologica; 2019; 241(1):24-31. PubMed ID: 29945143
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion.
Sharma S; ; Khan M; Chaturvedi A
Ophthalmol Ther; 2020 Sep; 9(3):625-639. PubMed ID: 32617913
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab.
Verma L; Thulasidas M; Purohit A; Gupta A; Narula R; Talwar D
Indian J Ophthalmol; 2021 Feb; 69(2):347-351. PubMed ID: 33463589
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World's First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration.
Sharma S; Khan M; Chaturvedi A;
Ophthalmol Ther; 2020 Mar; 9(1):103-114. PubMed ID: 31883056
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion:
Pielen A; Feltgen N; Hattenbach LO; Hoerauf H; Bertelmann T; Quiering C; Vögeler J; Priglinger S; Lang GE; Schmitz-Valckenberg S; Wolf A; Rehak M
Curr Eye Res; 2020 May; 45(5):604-614. PubMed ID: 31665935
[No Abstract] [Full Text] [Related]
7. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
[TBL] [Abstract][Full Text] [Related]
8. Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.
Sharma S; Sharma T; Prasad S; Gopalakrishnan M; Chaturvedi A
Ophthalmol Ther; 2021 Sep; 10(3):431-443. PubMed ID: 34155608
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
[TBL] [Abstract][Full Text] [Related]
10. Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence.
Kelkar AS; Kelkar J; Bolisetty M; Kelkar SB
Indian J Ophthalmol; 2021 Jun; 69(6):1469-1474. PubMed ID: 34011722
[TBL] [Abstract][Full Text] [Related]
11. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
[TBL] [Abstract][Full Text] [Related]
12. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial.
Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; de Jong-Hesse Y; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
Ophthalmol Retina; 2020 Jun; 4(6):576-587. PubMed ID: 32107188
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B).
Hattenbach LO; Feltgen N; Bertelmann T; Schmitz-Valckenberg S; Berk H; Eter N; Lang GE; Rehak M; Taylor SR; Wolf A; Weiss C; Paulus EM; Pielen A; Hoerauf H;
Acta Ophthalmol; 2018 Feb; 96(1):e10-e18. PubMed ID: 28251811
[TBL] [Abstract][Full Text] [Related]
14. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
15. Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.
Campochiaro PA; Hafiz G; Mir TA; Scott AW; Solomon S; Zimmer-Galler I; Sodhi A; Duh E; Ying H; Wenick A; Shah SM; Do DV; Nguyen QD; Kherani S; Sophie R
Ophthalmology; 2015 Jul; 122(7):1426-37. PubMed ID: 25972260
[TBL] [Abstract][Full Text] [Related]
16. RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data.
Chatziralli I; Theodossiadis G; Chatzirallis A; Parikakis E; Mitropoulos P; Theodossiadis P
Retina; 2018 Mar; 38(3):559-568. PubMed ID: 28248827
[TBL] [Abstract][Full Text] [Related]
17. Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study.
Wroblewski JJ; Hu AY
Ophthalmic Surg Lasers Imaging Retina; 2016 Oct; 47(10):914-923. PubMed ID: 27759857
[TBL] [Abstract][Full Text] [Related]
18. Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence.
Soman M; Nair I; Sheth JU; Nair U
Ophthalmol Ther; 2022 Jun; 11(3):1175-1186. PubMed ID: 35412266
[TBL] [Abstract][Full Text] [Related]
19. Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia.
Keilani C; Halalchi A; Wakpi Djeugue D; Regis A; Abada S
J Fr Ophtalmol; 2016 Dec; 39(10):816-821. PubMed ID: 27865689
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
